Details of the Drug

General Information of Drug (ID: DM3FPAQ)

Drug Name

Anifrolumab

Indication

Disease Entry	ICD 11	Status	REF
Systemic lupus erythematosus	4A40.0	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans

ATC Code

L04AA51: Anifrolumab

L04AA: Selective immunosuppressants

L04A: IMMUNOSUPPRESSANTS

L04: IMMUNOSUPPRESSANTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 907 mgday/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 82.4 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.72 h [2]
Clearance: The sytemic clearance of drug is 0.193 L/day [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.84 days (for a 0.1 mg/kg single dose) [4]
Metabolism: The drug is metabolized via the catabolized to smaller oligopeptides and individual amino acids [5]
Vd: The volume of distribution (Vd) of drug is 6.23 L [3]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon alpha/beta receptor 2 (IFNAR2)	TTMQB37	INAR2_HUMAN	Antagonist	[6]
Interferon gamma receptor (IFNGR2)	TT13TL0	INGR2_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761123.
2	Tummala R, Rouse T, Berglind A, Santiago L: Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018 Mar 23;5(1):e000252. doi: 10.1136/lupus-2017-000252. eCollection 2018.
3	FDA Approved Drug Products: Saphnelo (Anifrolumab-fnia) Intravenous Injection
4	Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014 Feb 24;16(1):R57. doi: 10.1186/ar4492.
5	Veve MP, Wagner JL: Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)